Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 341

1.

Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Adult Patients.

Coltro G, Antelo G, Lasho TL, Finke CM, Pardanani A, Gangat N, Carr RM, Binder M, Mangaonkar AA, Ketterling R, Fernandez-Zapico ME, Robertson KD, Bosi A, Vannucchi AM, Tefferi A, Patnaik MM.

Am J Hematol. 2020 Jan 10. doi: 10.1002/ajh.25721. [Epub ahead of print] No abstract available.

PMID:
31925810
2.

Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.

Coltro G, Mangaonkar AA, Lasho TL, Finke CM, Pophali P, Carr R, Gangat N, Binder M, Pardanani A, Fernandez-Zapico M, Robertson KD, Bosi A, Droin N, Vannucchi AM, Tefferi A, Hunter A, Padron E, Solary E, Patnaik MM.

Leukemia. 2019 Dec 13. doi: 10.1038/s41375-019-0690-7. [Epub ahead of print]

PMID:
31836856
3.

Autologous stem cell transplantation is safe in selected elderly multiple myeloma patients.

Antonioli E, Nozzoli C, Buda G, Staderini M, Boncompagni R, Martini F, Petrini M, Bosi A, Saccardi R.

Eur J Haematol. 2020 Feb;104(2):138-144. doi: 10.1111/ejh.13357. Epub 2019 Dec 12.

PMID:
31762088
4.

A refinement approach in a mouse model of rehabilitation research. Analgesia strategy, reduction approach and infrared thermography in spinal cord injury.

Redaelli V, Papa S, Marsella G, Grignaschi G, Bosi A, Ludwig N, Luzi F, Vismara I, Rimondo S, Veglianese P, Tepteva S, Mazzola S, Zerbi P, Porcu L, Roughan JV, Parati G, Calvillo L.

PLoS One. 2019 Oct 30;14(10):e0224337. doi: 10.1371/journal.pone.0224337. eCollection 2019.

5.

Street art graffiti: Discovering their composition and alteration by FTIR and micro-Raman spectroscopy.

Bosi A, Ciccola A, Serafini I, Guiso M, Ripanti F, Postorino P, Curini R, Bianco A.

Spectrochim Acta A Mol Biomol Spectrosc. 2020 Jan 15;225:117474. doi: 10.1016/j.saa.2019.117474. Epub 2019 Aug 19.

PMID:
31454690
6.

Chemotherapy-related nail toxicity.

Antonioli E, Fani A, Sordi B, Puccini B, Bosi A.

Int J Hematol. 2019 Nov;110(5):519-520. doi: 10.1007/s12185-019-02724-9. Epub 2019 Aug 10. No abstract available.

PMID:
31401768
7.

Marine Toxins and Nociception: Potential Therapeutic Use in the Treatment of Visceral Pain Associated with Gastrointestinal Disorders.

Baj A, Bistoletti M, Bosi A, Moro E, Giaroni C, Crema F.

Toxins (Basel). 2019 Jul 31;11(8). pii: E449. doi: 10.3390/toxins11080449. Review.

8.

Treatment Patterns in Patients with Chronic-Phase Chronic Myeloid Leukaemia in Routine Clinical Practice: the SIMPLICITY Italian Population.

Abruzzese E, Bosi A, Breccia M, D'Adda M, Di Renzo N, Liberati AM, Porrini R, Orlandi EM, Pane F, Pungolino E, Sorà F, Stagno F, Sen GP, Gentilini F, De Solda F, Gambacorti-Passerini C.

Mediterr J Hematol Infect Dis. 2019 May 1;11(1):e2019025. doi: 10.4084/MJHID.2019.025. eCollection 2019.

9.

Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients.

Baron F, Efficace F, Cannella L, Willemze R, Vignetti M, Muus P, Marie JP, Ferrero D, Fazi P, La Sala E, Bourhis JH, Fabbiano F, Bosi A, Sborgia M, Martinelli G, Wittnebel S, Trisolini S, Petti MC, Halkes CJM, van der Velden WJFM, de Witte T, Amadori S, Zittoun RA, Suciu S.

Haematologica. 2020 Jan;105(1):e13-e16. doi: 10.3324/haematol.2019.221333. Epub 2019 May 16. No abstract available.

10.

Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT.

Baron F, Labopin M, Ruggeri A, Ehninger G, Bonifazi F, Stelljes M, Sanz J, Stuhler G, Bosi A, Kröger N, Van Lint MT, Ganser A, Forcade E, Mohty M, Gluckman E, Nagler A.

Blood Cancer J. 2019 Apr 12;9(4):46. doi: 10.1038/s41408-019-0204-x.

11.

Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML.

Bassan R, Intermesoli T, Masciulli A, Pavoni C, Boschini C, Gianfaldoni G, Marmont F, Cavattoni I, Mattei D, Terruzzi E, De Paoli L, Cattaneo C, Borlenghi E, Ciceri F, Bernardi M, Scattolin AM, Todisco E, Campiotti L, Corradini P, Cortelezzi A, Ferrero D, Zanghì P, Oldani E, Spinelli O, Audisio E, Cortelazzo S, Bosi A, Falini B, Pogliani EM, Rambaldi A.

Blood Adv. 2019 Apr 9;3(7):1103-1117. doi: 10.1182/bloodadvances.2018026625.

12.

Influence of Donor and Recipient Gender on Telomere Maintenance after Umbilical Cord Blood Cell Transplantation: A Study by the Gruppo Italiano Trapianto Di Midollo Osseo.

Derenzini E, Risso A, Ruella M, Spatola T, Milone G, Pioltelli P, Iori AP, Santarone S, Bosi A, Rambaldi A, Bacigalupo AP, Arcese W, Tarella C.

Biol Blood Marrow Transplant. 2019 Jul;25(7):1387-1394. doi: 10.1016/j.bbmt.2019.03.026. Epub 2019 Mar 30.

PMID:
30935966
13.

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey.

Innocenti R, Rigacci L, Restelli U, Scappini B, Gianfaldoni G, Fanci R, Mannelli F, Scolari F, Croce D, Bonizzoni E, Perrone T, Bosi A.

J Blood Med. 2018 Dec 27;10:21-27. doi: 10.2147/JBM.S186786. eCollection 2019. Erratum in: J Blood Med. 2019 Feb 08;10:69.

14.

Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group.

Patriarca F, Masciulli A, Bacigalupo A, Bregante S, Pavoni C, Finazzi MC, Bosi A, Russo D, Narni F, Messina G, Alessandrino EP, Carella AM, Milone G, Bruno B, Mammoliti S, Bruno B, Fanin R, Bonifazi F, Rambaldi A; Gruppo Italiano Trapianti di Midollo Osseo. (GITMO).

Biol Blood Marrow Transplant. 2019 May;25(5):932-940. doi: 10.1016/j.bbmt.2018.12.064. Epub 2018 Dec 20.

PMID:
30579966
15.

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.

Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV.

Haematologica. 2018 Dec;103(12):2079-2087. doi: 10.3324/haematol.2018.194118. Epub 2018 Sep 20.

16.

The human RNASET2 protein affects the polarization pattern of human macrophages in vitro.

Scaldaferri D, Bosi A, Fabbri M, Pedrini E, Inforzato A, Valli R, Frattini A, De Vito A, Noonan DM, Taramelli R, Mortara L, Acquati F.

Immunol Lett. 2018 Nov;203:102-111. doi: 10.1016/j.imlet.2018.09.005. Epub 2018 Sep 12.

PMID:
30218741
17.

Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT.

Christopeit M, Labopin M, Gorin NC, Saraceni F, Passweg J, Forcade E, Maertens J, Van Lint MT, Bosi A, Niederwieser D, Ehninger G, Polge E, Mohty M, Nagler A.

Am J Hematol. 2018 Dec;93(12):1532-1542. doi: 10.1002/ajh.25285. Epub 2018 Oct 26.

18.

Vitamin D Deficiency has a Negative Impact on Cetuximab-Mediated Cellular Cytotoxicity against Human Colon Carcinoma Cells.

Mortara L, Gariboldi MB, Bosi A, Bregni M, Pinotti G, Guasti L, Squizzato A, Noonan DM, Monti E, Campiotti L.

Target Oncol. 2018 Oct;13(5):657-665. doi: 10.1007/s11523-018-0586-x.

PMID:
30090970
19.

MiR-146a induction by cyanobacterial lipopolysaccharide antagonist (CyP) mediates endotoxin cross-tolerance.

Molteni M, Bosi A, Saturni V, Rossetti C.

Sci Rep. 2018 Jul 27;8(1):11367. doi: 10.1038/s41598-018-29820-w.

20.

The use of Deauville 5-point score could reduce the risk of false-positive fluorodeoxyglucose-positron emission tomography in the posttherapy evaluation of patients with primary bone lymphomas.

Rigacci L, Kovalchuk S, Berti V, Puccini B, Mannelli L, Benelli G, Dini C, Pupi A, Bosi A.

World J Nucl Med. 2018 Jul-Sep;17(3):157-165. doi: 10.4103/wjnm.WJNM_42_17.

21.

The Effect of Cyanobacterial LPS Antagonist (CyP) on Cytokines and Micro-RNA Expression Induced by Porphyromonas gingivalis LPS.

Molteni M, Bosi A, Rossetti C.

Toxins (Basel). 2018 Jul 16;10(7). pii: E290. doi: 10.3390/toxins10070290.

22.

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission.

Bocchia M, Sicuranza A, Abruzzese E, Iurlo A, Sirianni S, Gozzini A, Galimberti S, Aprile L, Martino B, Pregno P, Sorà F, Alunni G, Fava C, Castagnetti F, Puccetti L, Breccia M, Cattaneo D, Defina M, Mulas O, Baratè C, Caocci G, Sica S, Gozzetti A, Luciano L, Crugnola M, Annunziata M, Tiribelli M, Pacelli P, Ferrigno I, Usala E, Sgherza N, Rosti G, Bosi A, Raspadori D.

Front Oncol. 2018 May 30;8:194. doi: 10.3389/fonc.2018.00194. eCollection 2018.

23.

Natural Killer Cells from Malignant Pleural Effusion Are Endowed with a Decidual-Like Proangiogenic Polarization.

Bosi A, Zanellato S, Bassani B, Albini A, Musco A, Cattoni M, Desio M, Nardecchia E, D'Urso DG, Imperatori A, Dominioni L, Noonan DM, Mortara L, Bruno A.

J Immunol Res. 2018 Mar 29;2018:2438598. doi: 10.1155/2018/2438598. eCollection 2018.

24.

Natural Products with Toll-Like Receptor 4 Antagonist Activity.

Molteni M, Bosi A, Rossetti C.

Int J Inflam. 2018 Mar 1;2018:2859135. doi: 10.1155/2018/2859135. eCollection 2018. Review.

25.

A case of disseminated blastic plasmocytoid dendritic cell neoplasm.

Loscocco GG, Piccini M, Vergoni F, Vannucchi AM, Bosi A.

Am J Hematol. 2018 Nov;93(11):1433-1434. doi: 10.1002/ajh.25109. Epub 2018 Jul 24. No abstract available.

26.

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.

Tefferi A, Mudireddy M, Mannelli F, Begna KH, Patnaik MM, Hanson CA, Ketterling RP, Gangat N, Yogarajah M, De Stefano V, Passamonti F, Rosti V, Finazzi MC, Rambaldi A, Bosi A, Guglielmelli P, Pardanani A, Vannucchi AM.

Leukemia. 2018 May;32(5):1200-1210. doi: 10.1038/s41375-018-0019-y. Epub 2018 Feb 2.

27.

The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia.

Galimberti S, Bucelli C, Arrigoni E, Baratè C, Grassi S, Ricci F, Guerrini F, Ciabatti E, Fava C, D'Avolio A, Fontanelli G, Cambrin GR, Isidori A, Loscocco F, Caocci G, Greco M, Bocchia M, Aprile L, Gozzini A, Scappini B, Cattaneo D, Scortechini AR, La Nasa G, Bosi A, Leoni P, Danesi R, Saglio G, Visani G, Cortelezzi A, Petrini M, Iurlo A, Di Paolo A.

Oncotarget. 2017 Sep 30;8(50):88021-88033. doi: 10.18632/oncotarget.21406. eCollection 2017 Oct 20.

29.

Corrigendum to "Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia" [Int. Immunopharmacol. 44 (2017) 38-42].

Spadaro G, Vultaggio A, Bosi A, Reichert D, Janssen J, Lamacchia D, Nappi L, Pecoraro A, Milito C, Ferraro A, Matucci A, Bacchiarri F, Carrai V, Hibbeler A, Speckman E, Guarnieri C, Bongiovanni S, Quinti I.

Int Immunopharmacol. 2018 Apr;57:201. doi: 10.1016/j.intimp.2017.10.014. Epub 2017 Oct 28. No abstract available.

PMID:
29089244
30.

Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma.

Cencini E, Puccini B, Rigacci L, Fabbri A, Kovalchuk S, Mannelli L, Benelli G, Carfagno T, Simontacchi G, Bocchia M, Bosi A.

Leuk Lymphoma. 2018 Jun;59(6):1420-1426. doi: 10.1080/10428194.2017.1387909. Epub 2017 Oct 10.

PMID:
28994343
31.

Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT.

Baron F, Ruggeri A, Beohou E, Labopin M, Mohty M, Sanz J, Vigouroux S, Furst S, Bosi A, Chevallier P, Cornelissen JJ, Michallet M, Sierra J, Karakasis D, Savani BN, Gluckman E, Nagler A.

J Intern Med. 2018 Feb;283(2):178-189. doi: 10.1111/joim.12696. Epub 2017 Nov 6.

32.

The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study.

Galimberti S, Ciabatti E, Ercolano G, Grassi S, Guerrini F, Cecconi N, Rousseau M, Cervetti G, Mazziotta F, Iovino L, Falzetti F, Falcinelli F, Bosi A, Rigacci L, Kovalchuk S, Vallisa D, Macchia L, Ciancia E, Petrini M.

Front Pharmacol. 2017 Jun 29;8:413. doi: 10.3389/fphar.2017.00413. eCollection 2017.

33.

Inorganic nanoparticles as potential regulators of immune response in dendritic cells.

Fogli S, Montis C, Paccosi S, Silvano A, Michelucci E, Berti D, Bosi A, Parenti A, Romagnoli P.

Nanomedicine (Lond). 2017 Jul;12(14):1647-1660. doi: 10.2217/nnm-2017-0061. Epub 2017 Jun 21.

PMID:
28635380
34.

A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach.

Lanza F, Saraceni F, Pezzi A, Martino M, Bosi A, Cascavilla N, Musto P, Zuffa E, Tani M, Cellini C, Laszlo D, Bonifazi F; GITMO (Italian Society for Transplantation).

Am J Hematol. 2017 Sep;92(9):E557-E559. doi: 10.1002/ajh.24817. Epub 2017 Jul 24. No abstract available.

35.

A life-threatening ruxolitinib discontinuation syndrome.

Coltro G, Mannelli F, Guglielmelli P, Pacilli A, Bosi A, Vannucchi AM.

Am J Hematol. 2017 Aug;92(8):833-838. doi: 10.1002/ajh.24775. Epub 2017 Jun 1. No abstract available.

36.

Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen.

Dodero A, Patriarca F, Milone G, Sarina B, Miceli R, Iori A, Barretta F, Terruzzi E, Mussetti A, Pini M, Bosi A, Dominietto A, Cascavilla N, Onida F, Narni F, Farina L, Rambaldi A, Corradini P.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1102-1109. doi: 10.1016/j.bbmt.2017.03.031. Epub 2017 Apr 5.

37.

Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System.

Della Porta MG, Jackson CH, Alessandrino EP, Rossi M, Bacigalupo A, van Lint MT, Bernardi M, Allione B, Bosi A, Guidi S, Santini V, Malcovati L, Ubezio M, Milanesi C, Todisco E, Voso MT, Musto P, Onida F, Iori AP, Cerretti R, Grillo G, Molteni A, Pioltelli P, Borin L, Angelucci E, Oldani E, Sica S, Pascutto C, Ferretti V, Santoro A, Bonifazi F, Cazzola M, Rambaldi A.

Leukemia. 2017 Nov;31(11):2449-2457. doi: 10.1038/leu.2017.88. Epub 2017 Mar 21.

38.

CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features.

Mannelli F, Ponziani V, Bencini S, Bonetti MI, Benelli M, Cutini I, Gianfaldoni G, Scappini B, Pancani F, Piccini M, Rondelli T, Caporale R, Gelli AM, Peruzzi B, Chiarini M, Borlenghi E, Spinelli O, Giupponi D, Zanghì P, Bassan R, Rambaldi A, Rossi G, Bosi A.

Haematologica. 2017 Mar;102(3):529-540. doi: 10.3324/haematol.2016.151910. Epub 2016 Nov 10.

39.

Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study.

Rosti G, Petrini M, Bosi A, Galieni P, Bernardi D, Giglio G, Dorotea L, Falini B, Scelzi E, Veltri E, Castelli R, Longagnani C, Raggi T, Simonetti F.

Ther Adv Med Oncol. 2017 Jan;9(1):22-32. doi: 10.1177/1758834016670554. Epub 2016 Oct 22.

40.

Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

Todisco E, Ciceri F, Boschini C, Giglio F, Bacigalupo A, Patriarca F, Donnini I, Alessandrino EP, Arcese W, Iori AP, Marenco P, Cavattoni I, Chiusolo P, Terruzzi E, Castagna L, Santoro A, Bosi A, Oldani E, Bruno B, Bonifazi F, Rambaldi A.

Bone Marrow Transplant. 2017 Jul;52(7):955-961. doi: 10.1038/bmt.2016.325. Epub 2017 Jan 9.

PMID:
28067875
41.

Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease: An Italian Multicentric Retrospective Analysis on 94 Patients on Behalf of the Gruppo Italiano Trapianto di Midollo Osseo.

Malagola M, Cancelli V, Skert C, Leali PF, Ferrari E, Tiburzi A, Sala ML, Donnini I, Chiusolo P, Mussetti A, Battista M, Turra A, Cattina F, Rambaldi B, Schieppati F, Polverelli N, Bernardi S, Perucca S, Marini M, Laszlo D, Savignano C, Patriarca F, Corradini P, Piccirillo N, Sica S, Bosi A, Russo D.

Transplantation. 2016 Dec;100(12):e147-e155.

PMID:
27861297
42.

Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission.

Saraceni F, Bruno B, Lemoli RM, Meloni G, Arcese W, Falda M, Ciceri F, Alessandrino EP, Specchia G, Scimè R, Raimondi R, Bacigalupo A, Bosi A, Onida F, Rambaldi A, Bonifazi F, Olivieri A.

Bone Marrow Transplant. 2017 Jan;52(1):163-166. doi: 10.1038/bmt.2016.233. Epub 2016 Sep 26. No abstract available.

PMID:
27668760
43.

Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation.

Della Porta MG, Gallì A, Bacigalupo A, Zibellini S, Bernardi M, Rizzo E, Allione B, van Lint MT, Pioltelli P, Marenco P, Bosi A, Voso MT, Sica S, Cuzzola M, Angelucci E, Rossi M, Ubezio M, Malovini A, Limongelli I, Ferretti VV, Spinelli O, Tresoldi C, Pozzi S, Luchetti S, Pezzetti L, Catricalà S, Milanesi C, Riva A, Bruno B, Ciceri F, Bonifazi F, Bellazzi R, Papaemmanuil E, Santoro A, Alessandrino EP, Rambaldi A, Cazzola M.

J Clin Oncol. 2016 Oct 20;34(30):3627-3637. doi: 10.1200/JCO.2016.67.3616.

44.

Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients.

Bocchia M, Galimberti S, Aprile L, Sicuranza A, Gozzini A, Santilli F, Abruzzese E, Baratè C, Scappini B, Fontanelli G, Trawinska MM, Defina M, Gozzetti A, Bosi A, Petrini M, Puccetti L.

Oncotarget. 2016 Nov 1;7(44):72311-72321. doi: 10.18632/oncotarget.11100.

45.

The circadecadal rhythm of oscillation of umbilical cord blood parameters correlates with geomagnetic activity - An analysis of long-term measurements (1999-2011).

Scholkmann F, Miscio G, Tarquini R, Bosi A, Rubino R, di Mauro L, Mazzoccoli G.

Chronobiol Int. 2016;33(9):1136-1147. Epub 2016 Jul 13.

PMID:
27409251
46.

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.

Jakubowiak A, Offidani M, Pégourie B, De La Rubia J, Garderet L, Laribi K, Bosi A, Marasca R, Laubach J, Mohrbacher A, Carella AM, Singhal AK, Tsao LC, Lynch M, Bleickardt E, Jou YM, Robbins M, Palumbo A.

Blood. 2016 Jun 9;127(23):2833-40. doi: 10.1182/blood-2016-01-694604. Epub 2016 Apr 18.

47.

Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Czerw T, Labopin M, Gorin NC, Giebel S, Blaise D, Meloni G, Pigneux A, Bosi A, Veelken J, Ferrara F, Schaap N, Lemoli RM, Cornelissen JJ, Beohou E, Nagler A, Mohty M.

Cancer. 2016 Jun 15;122(12):1880-7. doi: 10.1002/cncr.29990. Epub 2016 Mar 28.

48.

Time related variations in stem cell harvesting of umbilical cord blood.

Mazzoccoli G, Miscio G, Fontana A, Copetti M, Francavilla M, Bosi A, Perfetto F, Valoriani A, De Cata A, Santodirocco M, Totaro A, Rubino R, di Mauro L, Tarquini R.

Sci Rep. 2016 Feb 24;6:21404. doi: 10.1038/srep21404.

49.

Assessment of exposure to pesticides during mixing/loading and spraying of tomatoes in the open field.

Aprea MC, Bosi A, Manara M, Mazzocchi B, Pompini A, Sormani F, Lunghini L, Sciarra G.

J Occup Environ Hyg. 2016;13(6):476-89. doi: 10.1080/15459624.2016.1143948.

PMID:
26853603
50.

High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry.

Martino M, Lanza F, Pavesi L, Öztürk M, Blaise D, Leno Núñez R, Schouten HC, Bosi A, De Giorgi U, Generali D, Rosti G, Necchi A, Ravelli A, Bengala C, Badoglio M, Pedrazzoli P, Bregni M; European Group for Blood and Marrow Transplantation Solid Tumor Working Party.

Biol Blood Marrow Transplant. 2016 Mar;22(3):475-81. doi: 10.1016/j.bbmt.2015.12.011. Epub 2015 Dec 23.

Supplemental Content

Support Center